INDICATIONS
Neratinib is indicated for the extended adjuvant treatment of adult patients with early stage
HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab based therapy.
Beacon Introduces Global Patient Support Program
Life saving drugs are either beyond the reach of general people or not available in many countries. Because of the patient exemptions for Bangladeshi companies,Beacon Pharmaceuticals can manufacture the patented drugs. As a support to global patient.
Registered and Licensed by Regulatory Authority of Bangladesh
Hernix is a registered product by the Directorate General of Drug Administration & Licensing Authority (Drugs) of Bangladesh. Drug Registration Number: 341-361-010 Inclusion Date: 00-00-0000 Valid up to: 00-00-0000